Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,361,850.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 45,000 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $96.93, for a total value of $4,361,850.00. Following the completion of the sale, the chief executive officer owned 643,209 shares of the company’s stock, valued at approximately $62,346,248.37. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Performance

BioNTech stock opened at $95.83 on Thursday. The firm has a 50 day simple moving average of $97.17 and a 200-day simple moving average of $95.00. The stock has a market cap of $24.23 billion, a price-to-earnings ratio of -12.24 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.60) EPS. On average, analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the company. Monaco Asset Management SAM purchased a new position in BioNTech in the 4th quarter valued at approximately $1,594,000. Hsbc Holdings PLC purchased a new stake in shares of BioNTech during the fourth quarter worth $4,969,000. Bank of America Corp DE raised its stake in shares of BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after acquiring an additional 474,796 shares in the last quarter. Finally, Amundi boosted its holdings in BioNTech by 24.5% in the first quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after purchasing an additional 25,506 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several recent analyst reports. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Canaccord Genuity Group cut their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Citigroup reduced their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.